Humacyte, Inc.
HUMA
$1.39
$0.010.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.02M | 2.04M | 1.57M | 818.00K | 517.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.02M | 2.04M | 1.57M | 818.00K | 517.00K |
| Cost of Revenue | 84.34M | 79.00M | 75.97M | 81.37M | 82.90M |
| Gross Profit | -82.32M | -76.97M | -74.40M | -80.55M | -82.38M |
| SG&A Expenses | 30.87M | 31.17M | 30.99M | 30.68M | 28.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.20M | 110.18M | 106.96M | 112.05M | 111.52M |
| Operating Income | -113.19M | -108.14M | -105.39M | -111.23M | -111.00M |
| Income Before Tax | -97.59M | -40.83M | -36.97M | -58.66M | -77.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.59 | -40.83 | -36.97 | -58.66 | -77.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.59M | -40.83M | -36.97M | -58.66M | -77.67M |
| EBIT | -113.19M | -108.14M | -105.39M | -111.23M | -111.00M |
| EBITDA | -105.89M | -100.79M | -98.02M | -103.92M | -103.77M |
| EPS Basic | -0.57 | -0.21 | -0.24 | -0.46 | -0.69 |
| Normalized Basic EPS | -0.33 | -0.31 | -0.40 | -0.47 | -0.50 |
| EPS Diluted | -0.58 | -0.21 | -0.24 | -0.46 | -0.69 |
| Normalized Diluted EPS | -0.33 | -0.31 | -0.40 | -0.47 | -0.50 |
| Average Basic Shares Outstanding | 698.38M | 632.03M | 572.23M | 533.33M | 497.06M |
| Average Diluted Shares Outstanding | 698.38M | 632.30M | 572.49M | 533.59M | 497.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |